Andrea Schneider, M.S., Ph.D.
Clinical Interests
From very early on in her academic career, Dr. Schneider focused on interdisciplinary research
with brain-behavior interactions and acquired broad knowledge in clinical psychology and medical
neuroscience, with specific training and expertise in ADHD, learning disabilities, and fragile X
spectrum disorders.
Being also a clinical psychologist, her other area of interest is intervention research. She completed
a pilot study of a phytopharmacological intervention (Ginkgo biloba) in dyslexia, and a study about
the efficacy of neurofeedback in ADHD. Currently, Dr. Schneider's main research interest is the
association between genetic and brain abnormalities underlying the neuropsychopathology,
behavioral, and psychiatric symptoms in individuals with the fragile X mutations. Her focus on a
number of psychophysiological indicators, like EEG/ERP measures in fragile X spectrum disorders
and ASD, prepulse inhibition, eye tracking, and biofeedback.
Dr. Schneider is strongly committed to understanding, prevention, care, and cure of
neurodevelopmental disorders.
Title
Specialty
Department
Assistant Research Scientist
Pediatric Psychology
MIND Institute
Pediatrics
Clinic
Center/Program Affiliation
Address/Phone
MIND Institute
UC Davis MIND Institute
Center for Mind and Brain,
UC Davis MIND Institute, 2825 50th St. Sacramento, CA 95817
Languages
Education
French, German, Russian
M.S., University of Postdam, Potsdam, 2001
Ph.D., University of Postdam, Potsdam, 2007
B.S., University of Potsdam, Postdam, 1997
Internships
Psychological-Psychotherapeutic Ward (outpatient), Potsdam, 2002-04
Andrea Schneider, M.S., Ph.D.
Fellowships
Professional Memberships
UC Davis MIND Institute, Postdoctoral Fellow, Sacramento, CA, 2008-11
American Psychological Association (APA)
FENS (Federation of European Neuroscience Society), and the Center for Cognitive Studies,
University Potsdam, Germany.
ffiliate of the ARTP (Autism Research and Treatment) program
MIND Institute
Select Recent Publications
Chonchaiya, W, Au, J, Schneider, A, Hessl, D, Harris, SW, Laird, M, Mu, Y, Tassone, F, Nguyen,
DV, Hagerman, RJ. Increased prevalence of seizures in boys who were probands with the FMR1
premutation and co-morbid autism spectrum disorder. Human Genetics, 2012; 131(4): 581-9.
Knox, A, Schneider, A, Abucayan, F, Hervey, C, Tran, C, Hessl, D, Berry-Kravis, E. Feasibility,
reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in
Fragile X syndrome (FXS). Journal of neurodevelopmental disorders, 2012; 4(1): 2.
Sorensen, PL, Basuta, K, Mendoza-Morales, G, Gane, LW, Schneider, A, Hagerman, R, Tassone, F.
A fragile X sibship from a consanguineous family with a compound heterozygous female and
partially methylated full mutation male. American journal of medical genetics. Part A, 2012; 158A
(5): 1221-4.
Wang, J.Y., Hessl, D., Iwahashi, C., Cheung, K., Schneider, A., Hagerman, R., Hagerman, P.,
Rivera, S. Influence of the fragile X mental retardation (FMR1) gene on the brain and working
memory in men with normal FMR1 alleles. NeuroImage, 2012; 12(65C): 288-298.
Wang, JM, Koldewyn, K, Hashimoto, R, Schneider, A, Le, L, Tassone, F, Cheung, K, Hagerman, P,
Hessl, D, Rivera, SM. Male carriers of the FMR1 premutation show altered hippocampal-prefrontal
function during memory encoding. Frontiers in human neuroscience, 2012; 6: 297.
Winarni, TI, Schneider, A, Borodyanskara, M, Hagerman, RJ. Early intervention combined with
targeted treatment promotes cognitive and behavioral improvements in young children with fragile
x syndrome. Case Reports in Genetics, 2012: 280813.
Yang, JC, Chan, SH, Khan, S, Schneider, A, Nanakul, R, Teichholtz, S, Niu, YQ, Seritan, A,
Tassone, F, Grigsby, J, Hagerman, PJ, Hagerman, RJ, Olichney, JM. Neural Substrates of Executive
Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a Brain Potential Study.
Cerebral cortex, 2012; 1-10.
Hessl, D, Wang, JM, Schneider, A, Koldewyn, K, Le, L, Iwahashi, C, Cheung, K, Tassone, F,
Hagerman, PJ, Rivera, SM. Decreased fragile X mental retardation protein expression underlies
amygdala dysfunction in carriers of the fragile X premutation. Biological psychiatry, 2011; 70(9):
859-65.
Andrea Schneider, M.S., Ph.D.
Bourgeois J.A., Seritan A.L., Casillas E.M., Hessl D., Schneider A., Yang Y., Kaur I., Cogswell J.B.,
Nguyen D.V., Hagerman R.J. Lifetime prevalence of mood and anxiety disorders in fragile X
premutation carriers. J Clin Psychiatry. 2011; 72(2): 175-82.
Schneider, A., Ballinger, E., Chavez, A., Tassone, F., Hagerman, RJ., Hessl, D. Prepulse Inhibition
in patients with fragile X-associated tremor ataxia syndrome. Neurobiol Aging, 2010; 33(6): 10451053.
© 2016 UC Regents